RMD · Resmed Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.43B | $1.42B | $1.34B | $1.28B | $1.29B | $1.22B | $1.16B | $1.20B | $1.10B | $1.03B |
| Cost of Revenue | $540.43M | $544.08M | $514.76M | $530.81M | $525.33M | $507.29M | $515.87M | $504.20M | $502.26M | $454.03M |
| Gross Profit | $890.98M | $878.72M | $820.82M | $751.27M | $766.41M | $717.22M | $646.93M | $692.78M | $600.06M | $579.72M |
| R&D | $94.27M | $90.97M | $87.32M | $81.37M | $83.94M | $79.52M | $73.88M | $77.07M | $75.71M | $69.87M |
| SG&A | $285.65M | $278.40M | $259.19M | $241.61M | $245.30M | $238.98M | $222.16M | $229.92M | $222.87M | $211.67M |
| Total Operating Expenses | $391.17M | $387.06M | $374.28M | $334.03M | $340.14M | $329.91M | $371.84M | $318.20M | $311.06M | $299.52M |
| D&A | $58.98M | $49.88M | $47.70M | $46.44M | $43.67M | $44.73M | $44.78M | $43.47M | $44.93M | $37.77M |
| Operating Income | $499.81M | $491.66M | $446.54M | $417.24M | $426.27M | $387.31M | $275.09M | $374.58M | $289.00M | $280.19M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $103.58M | $103.56M | $98.26M | $73.70M | $52.65M | $72.14M | $50.65M | $74.93M | $52.77M | $48.78M |
| Net Income | $398.73M | $392.59M | $348.54M | $344.62M | $365.04M | $311.36M | $208.80M | $300.49M | $219.42M | $224.91M |
| EPS - Basic | $2.74 | $2.69 | $2.38 | $2.35 | $2.49 | $2.12 | $1.42 | $2.04 | $1.49 | $1.53 |
| EPS - Diluted | $2.74 | $2.68 | $2.37 | $2.34 | $2.48 | $2.11 | $1.42 | $2.04 | $1.49 | $1.53 |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.66B | $1.42B | $1.38B | $1.21B | $932.71M | $426.36M | $238.36M | $237.91M | $209.10M | $227.89M |
| Accounts Receivable | $998.84M | $985.63M | $907.27M | $939.49M | $907.83M | $811.20M | $837.27M | $779.26M | $692.39M | $704.91M |
| Inventory | $911.88M | $922.04M | $945.81M | $927.71M | $862.64M | $917.98M | $822.25M | $829.46M | $958.23M | $998.01M |
| Accounts Payable | $273.30M | $250.41M | $266.77M | $278.16M | $222.56M | $249.28M | $237.73M | $177.44M | $177.05M | $150.76M |
| Current Assets | $4.06B | $3.82B | $3.63B | $3.51B | $3.21B | $2.64B | $2.36B | $2.35B | $2.30B | $2.37B |
| Total Assets | $8.78B | $8.50B | $8.31B | $8.17B | $7.57B | $7.22B | $6.87B | $6.81B | $6.74B | $6.75B |
| Current Liabilities | $1.35B | $1.25B | $1.26B | $1.02B | $940.52M | $904.08M | $910.65M | $773.03M | $770.80M | $758.53M |
| Long-term Debt | $404.17M | $403.92M | $408.66M | $658.39M | $663.13M | $667.58M | $697.31M | $997.05M | $1.35B | $1.43B |
| Total Liabilities | $2.29B | $2.18B | $2.19B | $2.21B | $2.02B | $2.03B | $2.01B | $2.18B | $2.49B | $2.62B |
| Stockholders' Equity | $6.49B | $6.32B | $6.12B | $5.97B | $5.55B | $5.20B | $4.86B | $4.63B | $4.25B | $4.13B |
| Retained Earnings | $6.96B | $6.65B | $6.34B | $6.08B | $5.78B | $5.23B | $4.99B | $4.77B | $4.40B | $4.25B |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | $457.32M | - | - | $325.54M | - | - | $286.28M | - |
| Investing Cash Flow | - | - | ($52.58M) | - | - | $2.15M | - | - | ($148.98M) | - |
| Financing Cash Flow | - | - | ($230.27M) | - | - | ($150.76M) | - | - | ($151.13M) | - |
| CapEx | - | - | $42.97M | - | - | $17.84M | - | - | $30.04M | - |
| Free Cash Flow | - | - | $414.36M | - | - | $307.70M | - | - | $256.25M | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q3 '24 | Q1 '24 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 62.2% | 61.8% | 61.5% | 58.6% | 59.3% | 58.6% | 55.6% | 57.9% | 54.4% | 56.1% |
| Operating margin | 34.9% | 34.6% | 33.4% | 32.5% | 33.0% | 31.6% | 23.7% | 31.3% | 26.2% | 27.1% |
| EBITDA margin | 39.0% | 38.1% | 37.0% | 36.2% | 36.4% | 35.3% | 27.5% | 34.9% | 30.3% | 30.8% |
| Net margin | 27.9% | 27.6% | 26.1% | 26.9% | 28.3% | 25.4% | 18.0% | 25.1% | 19.9% | 21.8% |
| Free cash flow margin | - | - | 31.0% | - | - | 25.1% | - | - | 23.2% | - |
| FCF / Net income | - | - | 1.19 | - | - | 0.99 | - | - | 1.17 | - |
| R&D / Revenue | 6.6% | 6.4% | 6.5% | 6.3% | 6.5% | 6.5% | 6.4% | 6.4% | 6.9% | 6.8% |
| SG&A / Revenue | 20.0% | 19.6% | 19.4% | 18.8% | 19.0% | 19.5% | 19.1% | 19.2% | 20.2% | 20.5% |
| Effective tax rate | 20.6% | 20.9% | 22.0% | 17.6% | 12.6% | 18.8% | 19.5% | 20.0% | 19.4% | 17.8% |
| Return on assets | 4.5% | 4.6% | 4.2% | 4.2% | 4.8% | 4.3% | 3.0% | 4.4% | 3.3% | 3.3% |
| Return on equity | 6.1% | 6.2% | 5.7% | 5.8% | 6.6% | 6.0% | 4.3% | 6.5% | 5.2% | 5.4% |
| Return on invested capital | 5.8% | 5.8% | 5.3% | 5.2% | 6.0% | 5.4% | 4.0% | 5.3% | 4.2% | 4.1% |
| Liquidity | ||||||||||
| Current ratio | 3.01 | 3.06 | 2.89 | 3.44 | 3.41 | 2.92 | 2.59 | 3.04 | 2.99 | 3.12 |
| Quick ratio | 2.33 | 2.32 | 2.13 | 2.53 | 2.49 | 1.91 | 1.69 | 1.97 | 1.75 | 1.81 |
| Cash ratio | 1.23 | 1.14 | 1.10 | 1.19 | 0.99 | 0.47 | 0.26 | 0.31 | 0.27 | 0.30 |
| Leverage | ||||||||||
| Debt / Equity | 0.06 | 0.06 | 0.07 | 0.11 | 0.12 | 0.13 | 0.14 | 0.22 | 0.32 | 0.35 |
| Debt / Assets | 0.05 | 0.05 | 0.05 | 0.08 | 0.09 | 0.09 | 0.10 | 0.15 | 0.20 | 0.21 |
| Debt / EBITDA | 0.72 | 0.75 | 0.83 | 1.42 | 1.41 | 1.55 | 2.18 | 2.38 | 4.05 | 4.50 |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.35 | 1.35 | 1.36 | 1.37 | 1.36 | 1.39 | 1.41 | 1.47 | 1.59 | 1.63 |
| Liabilities / Assets | 0.26 | 0.26 | 0.26 | 0.27 | 0.27 | 0.28 | 0.29 | 0.32 | 0.37 | 0.39 |
| Efficiency | ||||||||||
| Asset turnover | 0.16 | 0.17 | 0.16 | 0.16 | 0.17 | 0.17 | 0.17 | 0.18 | 0.16 | 0.15 |
| Inventory turnover | 0.59 | 0.59 | 0.54 | 0.57 | 0.61 | 0.55 | 0.63 | 0.61 | 0.52 | 0.45 |
| Days sales outstanding | 255d | 253d | 248d | 267d | 257d | 242d | 263d | 238d | 229d | 249d |
| Days inventory outstanding | 616d | 619d | 671d | 638d | 599d | 660d | 582d | 600d | 696d | 802d |
| Days payable outstanding | 185d | 168d | 189d | 191d | 155d | 179d | 168d | 128d | 129d | 121d |
| Cash conversion cycle | 686d | 703d | 729d | 714d | 701d | 723d | 676d | 710d | 797d | 930d |
| Valuation | ||||||||||
| P / E | 81.9x | 89.9x | 115.5x | 110.3x | 90.3x | 115.7x | 134.8x | 97.1x | 99.2x | 142.8x |
| P / B | 5.0x | 5.6x | 6.6x | 6.4x | 5.9x | 6.9x | 5.8x | 6.3x | 5.1x | 7.8x |
| P / S | 22.9x | 24.8x | 30.1x | 29.7x | 25.5x | 29.4x | 24.3x | 24.4x | 19.8x | 31.2x |
| EV / EBITDA | 56.3x | 63.2x | 79.4x | 80.9x | 69.6x | 84.0x | 89.7x | 71.7x | 68.7x | 105.1x |
| Growth | ||||||||||
| Revenue growth (YoY) | 10.8% | 11.0% | 9.1% | 10.3% | 7.9% | 11.1% | 12.5% | 7.2% | 16.0% | 15.5% |
| Revenue CAGR (3y) | 8.6% | 11.2% | 12.0% | 12.7% | 14.3% | 10.6% | 16.5% | 15.9% | 17.4% | 12.0% |
| Revenue CAGR (5y) | 13.2% | 14.1% | 14.4% | 11.7% | 10.9% | 12.4% | 12.3% | 12.6% | 13.4% | - |
| Gross profit growth (YoY) | 16.3% | 17.0% | 14.4% | 16.1% | 10.6% | 19.5% | 11.6% | 12.1% | 11.0% | 15.0% |
| Operating income growth (YoY) | 17.3% | 17.8% | 15.3% | 51.7% | 13.8% | 34.0% | -1.8% | 24.6% | 4.8% | 12.7% |
| Net income growth (YoY) | 9.2% | 13.9% | 11.9% | 65.0% | 21.5% | 41.9% | -7.2% | 29.2% | 4.2% | 11.5% |
| EPS growth (YoY) | 10.5% | 14.5% | 12.3% | 64.8% | 21.6% | 41.6% | -7.2% | 29.1% | 4.2% | 11.7% |
| EPS CAGR (3y) | 20.1% | 20.5% | 18.3% | 19.5% | 26.7% | 14.9% | 4.9% | - | 6.9% | 11.6% |
| EPS CAGR (5y) | - | 16.9% | 14.2% | 16.3% | 17.2% | 20.5% | 10.5% | 22.8% | 15.3% | 85.3% |
| FCF growth (YoY) | - | - | 34.7% | - | - | 20.1% | - | - | 1542.0% | - |
| FCF CAGR (5y) | - | - | 26.0% | - | - | 17.1% | - | - | 25.9% | - |
| Book value growth (YoY) | 17.1% | 5.9% | 17.8% | 22.7% | 19.8% | 22.2% | 17.8% | 17.7% | 23.8% | 22.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-06-30.
Business segments
$5.15B totalSleep And Breathing Health$4.50B · 87.5%
Residential Care Software$641.44M · 12.5%
Product / service
$5.15B totalSleep And Breathing Health$4.50B · 87.5%
Residential Care Software$641.44M · 12.5%
Geographic
$7.81B totalUS$3.29B · 42.1%
Rest Of World$1.86B · 23.8%
U.S.Canada And Latin America$1.65B · 21.2%
Combined Europe Asia And Other Markets$1.01B · 12.9%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing RESMED INC against the 5 most active filers in the same SIC group.
Dividends
$2.40/share trailing 12 months · +13.2% YoY
| Ex-date | Per share |
|---|---|
| May 14, 2026 | $0.6000 |
| Feb 12, 2026 | $0.6000 |
| Nov 13, 2025 | $0.6000 |
| Aug 14, 2025 | $0.6000 |
| May 8, 2025 | $0.5300 |
| Feb 13, 2025 | $0.5300 |
| Nov 7, 2024 | $0.5300 |
| Aug 15, 2024 | $0.5300 |
| May 8, 2024 | $0.4800 |
| Feb 7, 2024 | $0.4800 |
| Nov 8, 2023 | $0.4800 |
| Aug 16, 2023 | $0.4800 |
| May 10, 2023 | $0.4400 |
| Feb 8, 2023 | $0.4400 |
| Nov 9, 2022 | $0.4400 |
| Aug 17, 2022 | $0.4400 |
| May 11, 2022 | $0.4200 |
| Feb 9, 2022 | $0.4200 |
| Nov 9, 2021 | $0.4200 |
| Aug 18, 2021 | $0.4200 |
| May 12, 2021 | $0.3900 |
| Feb 10, 2021 | $0.3900 |
| Nov 10, 2020 | $0.3900 |
| Aug 19, 2020 | $0.3900 |